Brief: Aurobindo Pharma Says Curateq Biologics Announces Positive Phase 3 Results For Omalizumab Biosimilar Bp11
06/04/2026 12:24
April 6 (Reuters) - Aurobindo Pharma Ltd ARBN.NS: CURATEQ BIOLOGICS ANNOUNCES POSITIVE PHASE 3 RESULTS FOR OMALIZUMAB BIOSIMILAR BP11 PHASE 3 STUDY MET ALL PRIMARY ENDPOINTS IN CSU PATIENTS AT 300 MG DOSE Source text: ID:nNSE2RrdG0 Further company coverage: ARBN.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma Gets Tax Order Confirming Total Disputed Amount 46 Million Rupees
India's Aurobindo Pharma falls after US FDA flags observation at Telangana facility
Brief: Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma
Brief: Aurobindo Pharma Gets USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol
Brief: Aurobindo Pharma Says US FDA Inspected Unit-IV Of Apitoria Pharma From September 7 To September 11